Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy
Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
A Phase I trial of weekly topotecan in combination with sorafenib in treatment of relapsed
Small cell lung cancer (SCLC) has been commenced. In the present randomized phase 2 study,
the investigators will research whether Sorafenib maintenance prolongs progression free
survival (PFS) and overall survival (OS) in patients with ED-SCLC who achieved CR or PR after
platinum-based induction chemotherapy.